SkinBioTherapeutics Presents Successful Technical Launch of Zenakine™ at In-Cosmetics Global 2025
Why we think this is neutral
This RNS announcement does not contain any of the mandatory news types, such as contract news, order news, trading update, financing, funding, annual results, asset sale/disposal, flow testing, licence news, or delisting. Therefore, the sentiment score is set to neutral.
Key Points
- Croda Beauty team presented Zenakine™ to a full auditorium and received a standing ovation
- Additional benefits of Zenakine™ revealed, including improved cell longevity and skin regeneration for anti-ageing
- Management sees no reason behind the recent reduction in share price
Summary
The life science company presented its Zenakine™ product at the in-cosmetics global 2025 meeting, receiving a positive response from the audience.
SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announced that the Croda Beauty team held a successful technical presentation of Zenakine™ at the in-cosmetics Global 2025 meeting in Amsterdam. The presentation received a standing ovation from the full capacity auditorium and revealed additional benefits of the product, including improvement of cell longevity and skin regeneration for increased anti-ageing.
Key Dates
16 April 2025
Investor Meets Company Presentation
GENERAL UPDATE